Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group

Annals of Oncology

Volumn 16, Issue 8, 2005, Pages 1343-1351

  Campone, M ^a   Roche H ^b   Kerbrat, P ^c   Bonneterre, J ^d   Romestaing, P ^e   Fargeot, P ^f   Namer, M ^g   Monnier, A ^h   Montcuquet, P ⁱ   Goudier, M J ^j   Fumoleau, P ^f  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e Centre Hospitalier Jules Courmont   (France)

^f CENTRE GEORGES FRANÇOIS LECLERC   (France)

^g CENTRE ANTOINE LACASSAGNE   (France)

^h Centre Hospitalier André Boulloche   (France)

ⁱ Clinique Saint Vincent   (France)

^j Centre Hospitalier de Bretagne Sud   (France)

more..

Author keywords

Adjuvant chemotherapy; Breast cancer; Epirubicin; Secondary leukemia

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MITOXANTRONE; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LEUKEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER;

EID: 23844523516     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi251     Document Type: Article

References (31)

1. Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 1982; 307: 965-971.
2. Grunwald HW, Rosner F. Acute myeloid leukemia following treatment of Hodgkin's disease: A review. Cancer 1982; 50: 676-683.
3. Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet 1991; 55: 119-124.
4. Smith RE, Bryant J, DeCillis A et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 2003; 21: 1195-1204.
5. Pedersen-Bjergaard J, Sigsgaard TC, Nielson D et al. Acute monocytic or myelomonocytic leukemia with balanced chromosomal translocations to band 11q23 after therapy with 4-epidoxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 1992; 10: 1444-1451.
6. Riggi M, Riva A. Therapy-related leukemia: What is the role of 4-epi-doxorubicin? J Clin Oncol 1993; 11: 1430-1431.
7. Marty M. Epirubicin and the risk of leukemia: Not substantiated? International Collaborative Cancer Group Steering Committee. J Clin Oncol 1993; 11: 1431-1433.
8. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women woth node-positive breast cancer. J Clin Oncol 1998; 16: 2651-2658.
9. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-1391.
10. Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000; 109: 13-23.
11. Curtis RE, Boice JD Jr, Stovall M et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745-1751.
12. Valagussa P, Moliterni A, Terenziani M et al. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 1994; 5: 803-808.
13. Diamandidou E, Buzdar AU, Smith TL et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 1996; 14: 2722-2730.
14. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273: 542-547.
15. Tallman MS, Gray R, Bennett JM et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group experience. J Clin Oncol 1995; 13: 1557-1563.
16. Misset JL, di Palma M, Delgado M et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol 1996; 14: 1136-1145.
17. Budd GT, Green S, O'Bryan RM et al. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: An Intergroup study. J Clin Oncol 1995; 13: 831-839.
18. Bernard-Marty C, Mano M, Paesmans M et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann Oncol 2003; 14: 693-698.
19. Wils JA, Bliss JM, Marty M et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol 1999; 17: 1988-1998.
20. Crump M, Tu D, Shepherd L et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3066-3071.
21. Andersen MK, Christiansen DH, Jensen BA et al. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: Report on two new cases and review of the literature since 1992. Br J Haematol 2001; 114: 539-543.
22. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
23. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003; 21: 1431-1439.
24. Martin M, Pienkowski T, Mackey J et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Symposium, 26th Annual Meeting, San Antonio, TX, USA, 2003, 43 (Abstr).
25. Albain K, Ravdin P et al. Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: New Findings from Phase III South West Oncology Group Intergroup Trial S8814 (INT-0100). Proc Am Soc Clin Oncol 2001; 20: 94 (Abstr).
26. Haskell CM, Green SJ, Sledge GW et al. Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A→C) in breast cancer patients with 0-3 positive nodes (Intergroup 0137). Proc Am Soc Clin Oncol 2002; 21: 142 (Abstr).
27. Kaplan HG, Malmgren JA, Atwood M. Leukemia incidence following primary breast carcinoma treatment. Cancer 2004; 101: 1529-1536.
28. van der Hage JA, van de Velde CJH, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19: 4224-4237.
29. Coombes RC, Bliss JM, Wils J et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996; 14: 35-45.
30. Mouridsen H, Andersen J, Andersson M et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 1999; 18: 254 (Abstr).
31. Roché H, Spielmann M, Fumoleau P et al. Safety analysis of PACS 01 adjuvant trial comparing 6 cycles of FEC 100 to 3 cycles of FEC 100 followed by 3 cycles of docetaxel in node-positive breast cancer patients. Breast Cancer Symposium, 26th Annual Meeting, San Antonio, TX, USA, 2003, 144 (Abstr).